New hope for lymphoma patients: drug targets cancer without chemo
NCT ID NCT07128641
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called odronextamab in people with a slow-growing blood cancer (follicular lymphoma) who have not had treatment before and have low tumor burden. The goal is to see if the drug can shrink or eliminate the cancer. About 35 adults will receive the drug, and researchers will track how many achieve complete remission.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?